Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
ORKA - Oruka Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$153.25
DETAILS
HIGH:
$200.00
LOW:
$120.00
MEDIAN:
$155.50
CONSENSUS:
$153.25
UPSIDE:
81.36%
Stock News
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Therapeutics, Inc. (Nasdaq: ORKA) ("Oruka") today announced that Halozyme's wholly‑owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing
Oruka Therapeutics (NASDAQ: ORKA) reported 16-week interim results from EVERLAST-A, a double-blind, placebo-controlled phase II study evaluating ORKA-001, the company's extended half-life IL-23/p19 monoclonal antibody for moderate-to-severe plaque psoriasis. Management highlighted what it described as a potentially "category-winning" efficacy profile alongside a safety profile consistent with the IL-23 inhibitor class, and pointed to pharmacokinetic data supporting
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximately $700.4 million, before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. In addition, Oruka has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,449,000 shares of Oruka's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering are to be sold by Oruka. The offering is expected to close on or about April 30, 2026, subject to the satisfaction of customary closing conditions.
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.
Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001
Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001's half-life extension technology targets once-yearly dosing, aiming for best-in-class efficacy and competitive differentiation in a crowded biologics market. Key near-term catalysts include longer-term phase 2a follow-up data in H2 2026 and phase 2b EVERLAST-B dose-finding results in 2027 for ORKA-001.
Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance
Oruka Therapeutics Inc. (NASDAQ:ORKA) shares are up during Monday's premarket session following positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis.
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif.
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
MENLO PARK, Calif. , April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026.
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors
7,000 shares directly sold for a value of $463,000 on April 15, 2026, at a weighted average sale price of around $66.12 per share. This transaction represented 17% of Joana Goncalves's direct Common Stock holdings, reducing her direct position from 40,377 to 33,377 shares.
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week High Following Analyst Upgrade
Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $40.00 to $70.00. HC Wainwright currently has a buy rating on the stock. Oruka Therapeutics traded as high as $65.64 and last traded at $66.1010,
Price Targets
Oruka Therapeutics price target raised to $130 from $100 at UBS
$130.00
(was $95.17)
UBS
Piper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+'
$180.00
(was $54.71)
Yasmeen Rahimi
·
Piper Sandler
Oruka Therapeutics price target raised to $120 from $109 at Leerink
$120.00
(was $68.10)
Leerink Partners
Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
$120.00
(was $73.99)
H.C. Wainwright
Oruka Therapeutics price target raised to $100 from $75 at UBS
$100.00
(was $81.42)
UBS
Oruka Therapeutics price target raised to $165 from $85 at Wedbush
$165.00
(was $80.16)
Wedbush
Oruka Therapeutics price target raised to $160 from $78 at Barclays
$160.00
(was $80.35)
Etzer Darout
·
Barclays
Oruka Therapeutics price target raised to $200 from $125 at Guggenheim
$200.00
(was $81.11)
Guggenheim
Oruka Therapeutics price target raised to $151 from $78 at BTIG
$151.00
(was $82.36)
BTIG
Oruka Therapeutics price target raised to $85 from $45 at Wedbush
$85.00
(was $67.06)
Wedbush
BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2'
$73.00
(was $38.01)
Julian Harrison
·
BTIG
Oruka Therapeutics price target raised to $45 from $42 at Wedbush
$45.00
(was $30.28)
Wedbush
UBS Starts Oruka Therapeutics (ORKA) at Buy
$50.00
(was $26.62)
Michael Yee
·
UBS
Oruka Therapeutics initiated with an Overweight at Piper Sandler
$75.00
(was $28.38)
Piper Sandler
Oruka Therapeutics initiated with a Buy at Guggenheim
$60.00
(was $27.25)
Guggenheim
Oruka Therapeutics price target lowered to $40 from $45 at H.C. Wainwright
$40.00
(was $27.25)
Mitchell Kapoor
·
H.C. Wainwright
Oruka Therapeutics initiated with an Overweight at Barclays
$48.00
(was $24.49)
Barclays
Oruka Therapeutics initiated with an Outperform at Wolfe Research
$20.00
(was $13.70)
Andy Chen
·
Wolfe Research
Jefferies Starts Oruka Therapeutics (ORKA) at Buy
$40.00
(was $26.00)
Michael Yee
·
Jefferies
Oruka initiated with an Outperform at Wedbush
$40.00
(was $25.50)
David Nierengarten
·
Wedbush